» Articles » PMID: 12807941

Chapter 3: Cofactors in Human Papillomavirus Carcinogenesis--role of Parity, Oral Contraceptives, and Tobacco Smoking

Overview
Specialty Oncology
Date 2003 Jun 17
PMID 12807941
Citations 173
Authors
Affiliations
Soon will be listed here.
Abstract

It is now well established that infection with oncogenic human papillomavirus (HPV) types is the necessary cause of cervical cancer (CC) and its immediate precursor cervical intraepithelial neoplasia 3. However, HPV infection alone may not be sufficient to cause CC, and other exogenous and endogenous factors may exist that, in conjunction with HPV, influence the risk of progression from cervical HPV infection to CC. In this chapter, we review the evidence for the role of parity, oral contraceptive (OC) use, and tobacco smoking in CC. We also discuss limitations and methodologic problems encountered in assessing available data and outline recommendations for future research. Based on key studies on high-grade squamous intraepithelial lesions (HSILs) and CC conducted among HPV-positive women, it can be concluded that high parity, smoking, and less consistently long-term OC use are cofactors that may modulate the risk of progression from HPV infection to HSIL/CC. From a public health point of view, parity seems to be the behavioral cofactor explaining the highest proportion of CC cases among HPV-infected women. Smoking and long-term OC use may have a similar impact in populations that are heavily exposed to HPV and to these cofactors. Large prospective and retrospective cohort studies of HSIL and CC among middle-aged women in which several markers of HPV exposure are used and HPV persistence is documented would be valuable to study the role of these and other cofactors in HPV carcinogenesis. If confirmed, our conclusions may imply that multiparous women, women who are smokers, and women on long-term OC use may need closer surveillance for cytologic abnormalities and HPV infections than women in the general population.

Citing Articles

The Assessment of Knowledge About Cervical Cancer, HPV Vaccinations, and Screening Programs Among Women as an Element of Cervical Cancer Prevention in Poland.

Wdowiak K, Drab A, Filipek P, Religioni U J Pers Med. 2024; 14(12).

PMID: 39728052 PMC: 11678483. DOI: 10.3390/jpm14121139.


Association between TAB2 genetic polymorphisms and the susceptibility to cervical cancer: a case-control study.

Li Q, Su M, Wang Y, Li Z, Song Y, Zhou B Cancer Cell Int. 2024; 24(1):413.

PMID: 39702253 PMC: 11660587. DOI: 10.1186/s12935-024-03603-y.


Human papillomavirus serotypes and determinants among women with invasive cervical cancer in Katsina state, Northwest-Nigeria: a multicentre study.

Rasheed F, Yakasai I, Abdurrahman A, Usman A, Yusuf N Ecancermedicalscience. 2024; 18:1714.

PMID: 39021557 PMC: 11254414. DOI: 10.3332/ecancer.2024.1714.


Cervical cancer: Challenges and prevention strategies: A narrative review.

Tsige A, Beyene D Health Sci Rep. 2024; 7(6):e2149.

PMID: 38826620 PMC: 11139676. DOI: 10.1002/hsr2.2149.


Prevalence of cervical intraepithelial lesions and associated factors among women attending a cervical cancer clinic in Western Uganda; results based on Pap smear cytology.

Ssedyabane F, Niyonzima N, Nambi Najjuma J, Birungi A, Atwine R, Tusubira D SAGE Open Med. 2024; 12:20503121241252265.

PMID: 38764539 PMC: 11100407. DOI: 10.1177/20503121241252265.